Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04924777
Recruitment Status : Recruiting
First Posted : June 14, 2021
Last Update Posted : June 14, 2021
Sponsor:
Information provided by (Responsible Party):
Riphah International University

Brief Summary:
The study design is to determine the effectiveness of moderate physical activity on g;lycemic control in type 2 diabetes mellitus.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Other: Brisk Walk Other: Strength training Other: Aerobic Exercises Not Applicable

Detailed Description:
To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more significant result on glycemic control in type 2 diabetes and is sustainable in Pakistani society according to the socioeconomic status and cost effectiveness of the modes of moderate physical activity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus
Actual Study Start Date : April 1, 2021
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Brisk walk Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months

Experimental: Aerobic Training Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months

Experimental: Strength Training Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months




Primary Outcome Measures :
  1. HbA1c Levels [ Time Frame: 3 months ]
    Reduction in HbA1c levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants falling in this category would be recruited into the study. Male/female Diabetic type 2 patients Age: 30-70 years BMI >25 Overweight Fat % in male> 25 Fat % in female >35 HbA1c level more than 48mmol/mol or >6.5% Fasting Plasma Glucose level >126 mg/dl (7.0 mmol/l) Random Plasma glucose level >200 mg/dl (11.1 mmol/l) Physically active ( have no mobility problems)

Exclusion Criteria:

Participant failing to fall in this category would be excluded of the study. Type 1 diabetes Insulin dependant type 2 diabetes Gestational Diabetes Hypertension Cigarette smoking Cardiovascular Disease Cerebrovascular disease Cardiopulmonary Disorders Cognition Problems Peripheral Artery Disease Dyslipidemia Proliferative or preproliferative retinopathy Nephropathy Neuropathy


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04924777


Contacts
Layout table for location contacts
Contact: Waqar Ahmad Awan, PhD +923335348846 waqar.ahmed@riphah.edu.pk

Locations
Layout table for location information
Pakistan
Riphah Rehabilitation Center Recruiting
Islamabad, Pakistan, 44000
Contact: Zainab Qadri, MS-SPT    +00923355766117    zainabqadri02@gmail.com   
Sponsors and Collaborators
Riphah International University
Investigators
Layout table for investigator information
Principal Investigator: Waqar Ahmad Awan Riphah International University
Layout table for additonal information
Responsible Party: Riphah International University
ClinicalTrials.gov Identifier: NCT04924777    
Other Study ID Numbers: REC/0929 Zainab Qadri
First Posted: June 14, 2021    Key Record Dates
Last Update Posted: June 14, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases